Aberdeen Group plc trimmed its stake in Dyne Therapeutics, Inc. (NASDAQ:DYN – Free Report) by 12.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,353,554 shares of the company’s stock after selling 185,880 shares during the period. Aberdeen Group plc’s holdings in Dyne Therapeutics were worth $21,806,000 at the end of the most recent quarter.
A number of other hedge funds have also recently made changes to their positions in DYN. Russell Investments Group Ltd. boosted its stake in Dyne Therapeutics by 141.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 255,190 shares of the company’s stock worth $4,111,000 after purchasing an additional 149,637 shares in the last quarter. Pictet Asset Management Holding SA raised its position in Dyne Therapeutics by 7.4% during the 3rd quarter. Pictet Asset Management Holding SA now owns 20,805 shares of the company’s stock worth $335,000 after buying an additional 1,433 shares during the last quarter. Alps Advisors Inc. raised its holdings in shares of Dyne Therapeutics by 48.1% during the third quarter. Alps Advisors Inc. now owns 247,403 shares of the company’s stock worth $3,986,000 after purchasing an additional 80,321 shares during the last quarter. CenterBook Partners LP lifted its holdings in Dyne Therapeutics by 167.7% in the third quarter. CenterBook Partners LP now owns 57,650 shares of the company’s stock valued at $929,000 after acquiring an additional 36,112 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in Dyne Therapeutics during the third quarter worth approximately $154,000. 96.68% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of equities analysts have commented on the company. Morgan Stanley reduced their target price on Dyne Therapeutics from $45.00 to $36.00 and set an “overweight” rating for the company in a report on Wednesday, September 9th. Cantor Fitzgerald reiterated a “buy” rating on shares of Dyne Therapeutics in a report on Wednesday, September 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Thursday, October 15th. Robert W. Baird decreased their target price on shares of Dyne Therapeutics from $30.00 to $26.00 and set an “outperform” rating on the stock in a research report on Wednesday, September 9th. Finally, Raymond James Financial reissued a “strong-buy” rating and set a $37.00 price target on shares of Dyne Therapeutics in a research note on Tuesday, September 8th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $31.29.
Insider Transactions at Dyne Therapeutics
In other news, Director Brian Posner bought 2,500 shares of the stock in a transaction that occurred on Friday, October 2nd. The shares were purchased at an average cost of $16.00 per share, with a total value of $40,000.00. Following the completion of the acquisition, the director directly owned 27,000 shares in the company, valued at approximately $432,000. The trade was a 10.20% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Douglas Kerr sold 3,745 shares of Dyne Therapeutics stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $24.35, for a total transaction of $91,190.75. Following the completion of the transaction, the insider directly owned 163,854 shares in the company, valued at $3,989,844.90. This represents a 2.23% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 14,000 shares of company stock valued at $285,151. Company insiders own 9.46% of the company’s stock.
Dyne Therapeutics Trading Down 4.1%
Shares of NASDAQ DYN opened at $16.02 on Wednesday. The stock’s 50 day simple moving average is $16.72 and its 200 day simple moving average is $19.31. The company has a market cap of $3.00 billion, a price-to-earnings ratio of -4.41 and a beta of 1.22. The company has a current ratio of 12.99, a quick ratio of 12.99 and a debt-to-equity ratio of 0.21. Dyne Therapeutics, Inc. has a 12-month low of $14.00 and a 12-month high of $27.31.
Dyne Therapeutics (NASDAQ:DYN – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.15). During the same period last year, the company earned ($0.76) earnings per share. Equities research analysts expect that Dyne Therapeutics, Inc. will post -3.81 EPS for the current year.
Dyne Therapeutics Company Profile
Dyne Therapeutics is a clinical-stage biotechnology company developing therapies for genetically driven muscle diseases. Its research uses the FORCE platform, which is designed to deliver oligonucleotide medicines to muscle tissue. The company’s programs include DYNE-101 for myotonic dystrophy type 1 and DYNE-251 for Duchenne muscular dystrophy in patients whose genetic mutations are amenable to exon 51 skipping. Dyne has also pursued a program for facioscapulohumeral muscular dystrophy. Its therapies remain in development, and the company does not have an approved product.
Further Reading
- Five stocks we like better than Dyne Therapeutics
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Want to see what other hedge funds are holding DYN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dyne Therapeutics, Inc. (NASDAQ:DYN – Free Report).
Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
